Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ovid Therapeutics ( (OVID) ) has provided an announcement.
On June 23, 2025, Ovid Therapeutics entered into an agreement with Immedica Pharma AB to sell its future royalties related to ganaxolone, a medicine used for treating CDKL5 deficiency disorder, for $7.0 million. This transaction provides Ovid with non-dilutive funding to support its operations, while Immedica gains control over ganaxolone’s intellectual property rights, enhancing its focus on rare diseases.
The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.
Spark’s Take on OVID Stock
According to Spark, TipRanks’ AI Analyst, OVID is a Neutral.
Ovid Therapeutics’ stock score is primarily impacted by financial performance challenges including revenue inconsistency and profitability issues. Technical analysis indicates a bearish trend with no immediate signs of recovery. Valuation metrics further reflect financial instability. The lack of earnings call data and notable corporate events leaves these areas unaddressed.
To see Spark’s full report on OVID stock, click here.
More about Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company focused on developing small molecule medicines for brain conditions with significant unmet needs. The company is advancing a pipeline of novel, targeted small molecule candidates for neurological and neuropsychiatric disorders, including treatment-resistant seizures and other CNS disorders.
Average Trading Volume: 628,762
Technical Sentiment Signal: Sell
Current Market Cap: $21.45M
For detailed information about OVID stock, go to TipRanks’ Stock Analysis page.